Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

Quark will lead a lecture and present a poster on proprietary siRNA

targeting and delivery approaches

FREMONT, Calif., June 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced it will participate in the Cambridge Healthcare Institute's 9th Annual Beyond Genome Conference on June 8-11, 2008 at The Fairmont Hotel, San Francisco, CA.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals will be presenting a lecture, "Temporary Inhibition of p53 of siRNA for Prevention of Acute Renal Failure: From Concept to Clinical Trials," at 1:50 PM (PT) on June 11, 2008.

Dr. Feinstein's lecture will discuss AKIi-5 and Quark's proprietary concept of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute kidney injury (AKI) in response to ischemia-reperfusion stress. Following a successful preclinical program focused on safety, AKIi-5 is currently in Phase I clinical trials and represents the first ever systemic dosing of an siRNA in humans.

Dr. Swetlana Boldin-Adamsky, Project Director of Quark, will give a poster presentation, "Non-invasive Aerosol siRNA Delivery for the Treatment of Lung Tumors." The poster will discuss direct delivery of siRNA to the respiratory system by inhalation, a potential delivery method for various disorders, including lung cancer. Remarkably, the anti-cancer siRNA target utilized in these studies was discovered using Quark's proprietary BiFAR functional gene discovery platform. Targeting this gene for cancer treatment is covered by Quark's intellectual property.

Dr. Feinstein stated, "We are excited to participate in this year's Beyond Genome conference. We have successfully administered the first siRNA drug candidate systemically in humans with the initiation of our AKIi-5 Phase I clinical trial. This acc
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... perfect example of the wonders of nanotechnology, in which common ... new and exciting possibilities. , Graphene ... graphitic carbon, which is used to make the pigment that ... to a one-atom-thick sheet. Graphene is among the strongest materials ...
... will result in over $80 million reduction in 2009 ... Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced a corporate ... 25 percent, or 340,employees, and reduce anticipated 2009 cash ... reduction are part of the,Company,s business plan to be ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today financial ... 30, 2008., Third Quarter and Nine Months Financial ... months ended Sept. 30, 2008, was,$3.8 million and $12.2 ... in 2007. Revenue in the third quarter and nine,months ...
Cached Biology Technology:Researchers discover method for mass production of nanomaterial graphene 2Researchers discover method for mass production of nanomaterial graphene 3Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 2Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6
(Date:9/18/2014)... developed a unique method to use microbes buried in ... , The first microbe-powered, self-sustaining wastewater treatment system ... clean up waste from large farming operations and rural ... Haluk Beyenal and graduate student Timothy Ewing in the ... in the online edition of Journal of Power ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... System is used in conjunction ... PCR of problematic and/or GC-rich ... Solution with 10X PCRX Amplification ... broader magnesium concentration broader annealing ...
MAGP-2 (C-19)...
Biology Products: